Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
11 mai 2021 09h05 HE
|
Vallon Pharmaceuticals Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 ...
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
07 mai 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:...
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
26 avr. 2021 09h05 HE
|
Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
13 avr. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
29 mars 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
03 mars 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
23 févr. 2021 09h05 HE
|
Vallon Pharmaceuticals Inc.
- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
12 févr. 2021 15h30 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
09 févr. 2021 22h24 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
19 janv. 2021 08h30 HE
|
Vallon Pharmaceuticals Inc.
ADAIR demonstrated bioequivalence to immediate release (IR) d-AMPH when administered orally and appears to be less desirable to recreational drug abusers when snorted compared to currently available...